Previous 10 | Next 10 |
2023-03-09 07:30:00 ET Summary Aclaris Therapeutics reported disappointing marks for zunsemetinib’s “ATI-450” Phase IIa trial for moderate to severe hidradenitis suppurativa. The share price has been nearly chopped in half. The trial missed the primary and sec...
2023-03-06 17:51:13 ET The major U.S. equity averages posted a mixed performance on Monday, holding steady after the gains recorded at the end of last week. Wall Street looked ahead to an appearance by Federal Reserve Chair Jerome Powell, who is scheduled to appear before Congress starting ...
2023-03-06 14:32:00 ET The stock market got off to a solid start on Monday, although there was a considerable disparity among different kinds of stocks. Small-cap indexes were down sharply, but the Dow Jones Industrial Average (DJINDICES: ^DJI) was higher by about a quarter-percent ...
2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...
2023-03-06 11:50:33 ET Shares of Aclaris Therapeutics (NASDAQ: ACRS) were crashing 41.7% lower as of 11:29 a.m. ET on Monday. The huge decline came after the company announced preliminary top-line results from a phase 2a clinical study evaluating zunsemetinib (ATI-450) in treating m...
2023-03-06 10:00:19 ET Gainers: BridgeBio Pharma ( BBIO ) +67% . Armata Pharmaceuticals ( ARMP ) +23% . TCR2 Therapeutics ( TCRR ) +21% . Euda Health ( EUDA ) +12% . Kala Pharmaceuticals ( KALA ) +16% . Losers: Aclaris...
2023-03-06 08:36:42 ET Aclaris Therapeutics ( NASDAQ: ACRS ) oral drug zunsemetinib (ATI-450) did not meet the main goal of a phase 2a trial in patients with with moderate to severe hidradenitis suppurativa (HS). HS is a condition which causes small, painful lumps ...
2023-03-06 08:17:23 ET Aclaris Therapeutics ( ACRS ) -38% after preliminary topline data from 12-week Phase 2a study did not meet primary or secondary efficacy endpoints in hidradenitis suppurativa . Esperion Therapeutics ( ESPR ) -27% amid Nexletol data ...
- Study Did Not Meet Primary or Secondary Efficacy Endpoints in Hidradenitis Suppurativa - Overall Safety Profile and PK/PD Generally Consistent with Observations in Prior Studies of Zunsemetinib WAYNE, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ...
Aclaris Therapeutics press release ( NASDAQ: ACRS ): Q4 GAAP EPS of -$0.41 beats by $0.05 . Revenue of $7.75M (+416.7% Y/Y) beats by $5.76M . As of December 31, 2022, Aclaris had aggregate cash, cash equivalents and marketable securities of $229.8 million compared to $...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...